Market Watch: Mesoblast shares down 14%
Monday, 31 October, 2011
The share price of stem cell specialists Mesoblast (ASX:MSB) shed 14% of its value in trading on Friday and today, down from $9.39 at Thursday’s close of trading to $8.25 as of midday today.
The drop was precipitated by Macquarie Research updating its rating for the biotech to “underperform”.
Other analysts have recently rated Mesoblast as “buy”, with Nomura setting a target price of $10.15 and Bell Potter $16.00 both only one month ago.
Late last year Mesoblast wowed the industry with its monumental deal with Cephalon, and recently announced it was partnering with Lonza to manufacture it’s off-the-shelf mesenchymal precursor stem cells.
Follow this link for a detailed profile of Mesoblast and its technology, and an interview with its CEO, Professor Silviu Itescu.
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
Over-the-counter pain relievers may improve concussion recovery
People who take over-the-counter pain relievers after a concussion may recover faster than those...
